How to Choose a Mammography System

What hospital radiology departments, women's imaging centers, and mobile screening operators need to know before committing capital to a breast imaging platform.

What this is and who buys it

A mammography system is a dedicated low-dose X-ray unit engineered specifically for breast tissue imaging, with detector sensitivities, compression mechanisms, and dose protocols that have no direct equivalent in general radiography. The two dominant acquisition modes are full-field digital mammography (FFDM), which produces a single 2D projection image, and digital breast tomosynthesis (DBT), which sweeps an X-ray tube across an arc to reconstruct the breast in 1 mm cross-sectional slices. These are not interchangeable technologies — DBT reduces the tissue-overlap problem that causes false positives and missed lesions in standard 2D imaging, which is why, as of March 2025, approximately 92% of U.S. accredited mammography facilities operate at least one DBT-capable unit [S2]. For new procurements in 2025–2026, DBT capability is effectively the baseline, not a premium feature.

Buyers span a wide range of facility types: hospital-based breast centers that need integrated screening, diagnostic, and biopsy workflows; outpatient women's imaging chains prioritizing throughput and patient experience; community and critical-access hospitals looking to offer DBT without premium capital; mobile mammography programs with strict footprint and power constraints; and surgical or oncology practices running a single diagnostic unit alongside stereotactic biopsy. Each profile has meaningfully different priorities around throughput, gantry configurability, AI licensing economics, and service coverage — decisions that should be locked in before evaluating specific platforms.

The clinical and regulatory stakes in mammography procurement are also higher than in most imaging modalities. Every U.S. facility must hold active MQSA certification, maintain ACR or state-body accreditation, and sustain a continuous quality-control program. A misconfigured purchase — wrong software clearance, non-compliant monitor, or an unlicensed synthesized-2D module — can suspend billing or trigger an MQSA citation before the first patient is imaged.

Key decision factors

2D versus DBT and sweep angle. All new procurements should default to DBT unless budget or facility size make it genuinely impractical. The technical nuance buyers often miss is that manufacturers differ significantly in their tomosynthesis acquisition geometry: angular sweep ranges from roughly 15° to 50° depending on platform, and the choice trades in-plane spatial resolution against depth resolution [S12]. Wider-sweep designs generate more sharply separated slices; narrower-sweep designs preserve higher in-plane sharpness. Neither is universally superior — the right choice depends on your radiologist workflows, so request sample DICOM datasets from each vendor before any capital commitment.

Synthesized 2D imaging. DBT by itself doubles the acquisition — historically requiring a separate 2D exposure — which increases dose and acquisition time. Synthesized 2D modules (marketed under various trade names by different manufacturers) reconstruct a 2D-equivalent image from the tomosynthesis data itself, reducing total radiation dose by close to 50% compared to combined 2D+DBT acquisition [S7]. Confirm that any synthesized-2D module shipping with the unit carries its own FDA 510(k) clearance and is included in the software license, not priced separately after contract signature.

Detector type and lifecycle. Premium systems use amorphous selenium direct-conversion flat-panel detectors, which offer excellent DQE (detective quantum efficiency) at mammographic energy ranges. A well-maintained detector can run 10–15 years, but replacement cost routinely exceeds $100,000 — a number that changes the TCO calculation dramatically on refurbished units [S9]. Always obtain the detector's serial number, manufacture date, and pixel-defect map before purchasing any pre-owned system.

Biopsy and contrast-enhanced mammography. Add-on capabilities — stereotactic or tomosynthesis-guided biopsy, contrast-enhanced mammography (CEM) — are not universally compatible across gantry platforms, and some require dedicated prone biopsy tables rather than upright add-ons. If your facility plans to perform image-guided biopsy or CEM on the same gantry that handles screening, that decision must drive platform selection from the outset, not be retrofitted later.

AI detection software. FDA-cleared AI detection tools (multiple cleared products now exist across vendors) are increasingly expected by radiologists and referenced in accreditation contexts. The financial model matters as much as the clinical claims: most AI tools are licensed per-study or per-year, not included in the capital price. A license running $20,000–$60,000 annually is a material recurring cost that belongs in the total cost of ownership analysis alongside service contracts and tube replacement.

Workstation and display. Mammography review monitors require their own FDA clearance for mammographic image display — a minimum of 5 megapixels — and cannot be substituted with standard radiology or general-purpose displays [S1]. This applies to both the primary acquisition workstation and any remote reading station intended for mammographic interpretation. Verify 510(k) clearance numbers for every display in the proposed configuration.

What it costs

Mammography pricing spans a wide range depending on system generation, DBT capability, and whether the unit is new or refurbished. Installation, AI licensing, and service contracts are always additional. Publicly verified price bands (capital equipment only, before installation and software) are approximately [S8, S10]:

• Entry: $50,000–$120,000 — Refurbished 2D-only FFDM systems. Appropriate only as a backup unit or for facilities with a documented upgrade path; 2D-only resale value has largely collapsed as DBT adoption saturates the market.
• Mid: $125,000–$265,000 — Refurbished DBT-capable systems or new entry/mid-tier 3D configurations. This tier covers the broadest range of community hospital and outpatient imaging center needs.
• Premium: $350,000–$550,000+ — New, current-generation DBT systems from major manufacturers, before biopsy add-ons, AI licensing, and installation (which adds $25,000–$45,000 for new systems) [S11].

Common use cases

Mammography procurement decisions look quite different depending on the clinical context. The same gantry specification that suits a high-volume urban breast center will be over-engineered and over-priced for a rural critical-access hospital doing 800 screens per year.

• Hospital-based breast centers: High-volume screening, diagnostic workup, and biopsy — premium current-generation DBT with integrated upright or prone biopsy capability and CEM.
• Outpatient women's imaging centers: Mid-tier or premium DBT focused on throughput (6–8 patients/hour), often paired with automated breast ultrasound (ABUS); AI licensing often justified by volume.
• Community and critical-access hospitals: Mid-tier or refurbished DBT to meet MQSA requirements and offer tomosynthesis without premium capital outlay.
• Mobile mammography coaches: Compact-footprint units with robust parts availability; ruggedized installation to 208/240V mobile power; prioritize platforms with the broadest third-party service coverage given geographic service limitations.

Regulatory and compliance

Mammography is one of the most heavily regulated imaging modalities under U.S. federal law. FFDM devices are classified as Class II (special controls) under 21 CFR 892.1715, product code MUE [S1]. DBT was originally designated Class III, requiring a premarket approval pathway, though reclassification considerations have been ongoing [S13]. Every U.S. facility — regardless of ownership structure — must hold active MQSA certification, which requires applying to an FDA-approved accreditation body (the ACR, or the states of Arkansas and Texas), passing periodic clinical-image quality review, and maintaining documented personnel qualifications [S2, S5]. Annual medical physicist surveys are mandated under 21 CFR 900.12(e)(10) [S3], and facilities are subject to at least annual MQSA inspections. Per-view radiation dose must remain below 3 mGy [S2].

Beyond MQSA, applicable standards include IEC 60601-1 (general electrical safety), IEC 60601-2-45 (specific to mammographic X-ray equipment), and DICOM Mammography Image Object definitions for PACS integration. HIPAA obligations apply to all PHI stored or transmitted through the acquisition workstation and PACS. Confirm CMS reimbursement eligibility before imaging the first patient: CMS requires documented FDA digital approval notification through ACR before billing for digital mammography [S5].

Service, training, and total cost of ownership

Budget 6–10 weeks for installation of a new system, encompassing site preparation (lead shielding, dedicated 208/240V circuit, HVAC for detector electronics), physicist acceptance testing, and QC baseline establishment [S3]. A medical physicist must be involved from planning through initial QC implementation — this is not optional and should be contracted before equipment delivery. Daily, weekly, and monthly QC tests (phantom image, flat-field, compression force, AEC) are performed by the lead technologist using OEM-specific ACR checklists and are an MQSA requirement.

Annual OEM service contracts typically run $35,000–$55,000; independent service organizations (ISOs) with dedicated mammography-trained engineers generally price at $25,000–$40,000, representing a 20–35% savings [S11]. The savings are real, but verify the ISO has mammography-specific engineers and OEM-equivalent calibration tools — general X-ray engineers are not qualified to service mammography detectors. X-ray tubes last roughly 5–8 years at typical screening volumes; detector modules can run 10–15 years. Model useful equipment life at ~7 years for TCO purposes, though many facilities run systems longer when parts remain available.

Red flags to watch for

Purchasing a 2D-only system in 2025–2026 without a hardware-verified upgrade path to DBT is a capital allocation error — older analog systems cannot be converted, and 2D-only resale values have largely collapsed as the market saturates with DBT [S9]. Refurbished units sold by brokers without OEM-grade detector testing, current FDA-cleared software versions, and formal MQSA acceptance documentation represent a materially different risk profile than units refurbished by qualified vendors — the distinction is worth pressing vendors on explicitly. AI and CEM software licenses priced outside the capital proposal can add $20,000–$60,000 annually and are sometimes disclosed only after a letter of intent is signed. Finally, never assume that a general radiology monitor qualifies for mammographic display — the 5 MP minimum and separate 510(k) clearance requirement is frequently missed, and billing on a non-compliant display station is an MQSA violation [S1].

Questions to ask vendors

1. Provide the FDA 510(k) or PMA number for the gantry, detector, synthesized-2D module, and AI software, and confirm which software version will be installed at go-live.
2. Deliver a written 7-year total cost of ownership covering capital, installation, annual service (OEM and ISO-eligible), tube replacement interval, detector warranty terms, and all AI and CEM license fees.
3. What is the contractual uptime guarantee, parts-on-site response time, and remote diagnostic capability — and are loaner units provided during extended downtime?
4. Is the system field-upgradable from DBT to contrast-enhanced mammography and integrated biopsy guidance, at what cost and with what expected downtime?
5. Provide MTBF data and contacts for five reference sites of comparable annual volume.
6. For refurbished units: provide the detector serial number, manufacture date, pixel-defect map, X-ray tube exposure count, and a complete scope-of-work document listing OEM parts used in refurbishment.

Alternatives

The refurbished market deserves serious evaluation, not reflexive avoidance. Refurbished DBT-capable systems from qualified vendors typically price at $125,000–$250,000 versus $350,000–$500,000 new — a 50–65% capital saving [S10]. The platform with the broadest third-party parts and engineer ecosystem in the U.S. currently accounts for approximately 70% of the installed base, which means parts availability, ISO coverage, and tube sourcing are meaningfully easier for that platform's pre-owned units than for lower-share competitors [S9].

On financing, a 5-year fair-market-value operating lease (typically 1.8–2.0% of capital per month) preserves cash and can bundle AI licensing into a single monthly payment — a useful structure when AI costs are recurring and uncertain. Outright capital purchase makes more sense for facilities planning to hold equipment 7 years or longer and willing to absorb residual value risk. ISO service contracts offer real savings, but only when the ISO can document mammography-specific engineer credentials. Finally, ABUS and breast MRI are clinical complements, not substitutes for a mammography platform: a Norwegian randomized trial of 29,453 women found DBT added approximately €8.50 per screened woman in total cost versus standard digital mammography [S6] — a number that should be modeled against reimbursement uplift, not used as a reason to default to 2D.

Sources

• FDA — Full Field Digital Mammography System Class II Special Controls Guidance (21 CFR 892.1715)
• FDA — Mammography Quality Standards Act (MQSA) and MQSA Program
• eCFR — 21 CFR Part 900 (Mammography)
• ACR — Mammography Accreditation Program
• AAFP — Digital Breast Tomosynthesis for Breast Cancer Screening (2021)
• Moshina et al. — Cost differences between DBT and DM in Norwegian screening (To-Be trial), PMC
• Block Imaging — 2026 Mammography Price Guide
• Block Imaging — Best Pre-Owned Mammography Systems (2025)
• ARRAD — New vs. Refurbished Hologic Mammography Cost Comparison
• Block Imaging — Mammography Service Contract Pricing
• MTMI — 3D Mammography / Tomosynthesis Technologist Guide
• MDDI — Medical Imaging: The Basics of FDA Regulation